{
  "pathways": [
    {
      "id": "510k",
      "name": "510(k) Premarket Notification",
      "description": "Demonstrates substantial equivalence to a legally marketed predicate device",
      "device_class": ["I", "II"],
      "typical_timeline_days": 90,
      "fda_fee_usd": 13000,
      "clinical_data_required": false,
      "requirements": [
        "Identify predicate device(s)",
        "Demonstrate same intended use",
        "Demonstrate similar technological characteristics",
        "Performance testing data",
        "Biocompatibility testing (if patient contact)"
      ],
      "advantages": [
        "Faster time to market",
        "Lower cost than PMA",
        "No mandatory clinical trials",
        "Established pathway with predictable review"
      ],
      "limitations": [
        "Requires existing predicate device",
        "Cannot claim significant new indications",
        "Limited to Class I or II devices"
      ],
      "bci_examples": [
        {
          "company": "Precision Neuroscience",
          "device": "Layer 7-T Cortical Interface",
          "clearance_number": "K242618",
          "clearance_date": "2025-03-30"
        },
        {
          "company": "Blackrock Neurotech",
          "device": "NeuroPort Array",
          "clearance_number": "K110010",
          "clearance_date": "2011"
        }
      ]
    },
    {
      "id": "de_novo",
      "name": "De Novo Classification Request",
      "description": "Pathway for novel, low-to-moderate risk devices without a predicate",
      "device_class": ["I", "II"],
      "typical_timeline_days": 150,
      "fda_fee_usd": 123000,
      "clinical_data_required": "varies",
      "requirements": [
        "Demonstrate device is novel (no predicate)",
        "Demonstrate low-to-moderate risk profile",
        "Propose device classification and controls",
        "Performance and safety testing"
      ],
      "advantages": [
        "Creates new regulatory pathway for similar devices",
        "Avoids PMA for novel low-risk devices",
        "Device becomes predicate for future 510(k)s"
      ],
      "limitations": [
        "Longer than 510(k)",
        "Higher FDA fee than 510(k)",
        "May face more FDA questions"
      ],
      "bci_examples": [
        {
          "company": "Neurolutions",
          "device": "IpsiHand",
          "clearance_date": "2021"
        }
      ]
    },
    {
      "id": "pma",
      "name": "Premarket Approval (PMA)",
      "description": "Most rigorous pathway for Class III high-risk devices",
      "device_class": ["III"],
      "typical_timeline_days": 180,
      "fda_fee_usd": 400000,
      "clinical_data_required": true,
      "requirements": [
        "Clinical trial data demonstrating safety and effectiveness",
        "Complete manufacturing information",
        "Proposed labeling",
        "Environmental assessment"
      ],
      "advantages": [
        "Clear pathway for high-risk devices",
        "Strong regulatory protection",
        "Comprehensive safety evaluation"
      ],
      "limitations": [
        "Longest timeline (often 3-7 years total)",
        "Most expensive pathway",
        "Requires extensive clinical trials"
      ],
      "bci_examples": [
        {
          "company": "Medtronic",
          "device": "DBS Activa/Percept",
          "pma_number": "P960009"
        }
      ]
    },
    {
      "id": "ide",
      "name": "Investigational Device Exemption (IDE)",
      "description": "Allows unapproved devices to be used in clinical studies",
      "device_class": ["II", "III"],
      "typical_timeline_days": 30,
      "fda_fee_usd": 0,
      "clinical_data_required": "generates data",
      "ide_types": [
        {
          "type": "Significant Risk (SR)",
          "description": "Requires FDA approval before study",
          "fda_approval_required": true
        },
        {
          "type": "Non-Significant Risk (NSR)",
          "description": "IRB approval only",
          "fda_approval_required": false
        }
      ],
      "requirements": [
        "IRB approval",
        "Informed consent",
        "Monitoring and reporting",
        "Investigational labeling"
      ],
      "bci_examples": [
        {
          "company": "Synchron",
          "device": "Stentrode",
          "study": "COMMAND",
          "nct_number": "NCT05035823",
          "ide_approval_date": "2021-08"
        },
        {
          "company": "Neuralink",
          "device": "N1 Implant",
          "study": "PRIME",
          "nct_number": "NCT06429735",
          "ide_approval_date": "2023-05"
        },
        {
          "company": "Paradromics",
          "device": "Connexus BCI",
          "study": "Connect-One",
          "ide_approval_date": "2025-11"
        }
      ]
    },
    {
      "id": "breakthrough",
      "name": "Breakthrough Device Designation",
      "description": "Voluntary program to expedite development and review of innovative devices",
      "device_class": ["II", "III"],
      "typical_timeline_days": 60,
      "fda_fee_usd": 0,
      "clinical_data_required": false,
      "requirements": [
        "Breakthrough technology or no approved alternative",
        "Addresses life-threatening or irreversibly debilitating condition",
        "Provides more effective treatment or diagnosis"
      ],
      "benefits": [
        "Priority FDA review",
        "Early FDA interaction",
        "Rolling submission capability",
        "Senior management involvement",
        "Potential TCET eligibility for Medicare"
      ],
      "bci_designations": [
        {
          "company": "Blackrock Neurotech",
          "device": "MoveAgain",
          "designation_date": "2021-11-16",
          "indication": "Paralysis"
        },
        {
          "company": "Synchron",
          "device": "Stentrode",
          "designation_date": "2020",
          "indication": "Paralysis"
        },
        {
          "company": "Neuralink",
          "device": "N1 Implant",
          "designation_date": "2020",
          "indication": "Paralysis"
        },
        {
          "company": "Neuralink",
          "device": "Blindsight",
          "designation_date": "2024-09",
          "indication": "Vision restoration"
        },
        {
          "company": "Cognixion",
          "device": "ONE Headset",
          "designation_date": "2023",
          "indication": "Communication"
        }
      ]
    },
    {
      "id": "hde",
      "name": "Humanitarian Device Exemption (HDE)",
      "description": "Pathway for devices treating conditions affecting ≤8,000 patients per year",
      "device_class": ["III"],
      "typical_timeline_days": 75,
      "fda_fee_usd": 0,
      "clinical_data_required": false,
      "requirements": [
        "HUD designation (condition affects ≤8,000/year)",
        "Probable benefit outweighs risks",
        "IRB approval required before use"
      ],
      "advantages": [
        "Exempt from effectiveness requirements",
        "Lower evidence threshold than PMA"
      ],
      "limitations": [
        "Limited patient population",
        "IRB approval at each institution",
        "Profit restrictions may apply"
      ]
    }
  ]
}
